<DOC>
	<DOCNO>NCT03091621</DOCNO>
	<brief_summary>To clarify effectiveness safety direct factor Xa inhibitor rivaroxaban domestic clinical use patient deep vein thrombosis pulmonary embolism</brief_summary>
	<brief_title>Japanese Registry Rivaroxaban Effectiveness &amp; Safety Prevention Recurrence Patients With Deep Vein Thrombosis Pulmonary Embolism</brief_title>
	<detailed_description>Research design : multicenter collaboration , prospective , non-interventional , observational research Research outline : Registration period : Dec 2016 ( ethic committee approval ) May 2018 ( 1 year 6 month ) Investigation period : Dec 2016 ( ethic committee approval ) Nov 2019 ( At least 1 year 6 month ) Target number participant : 1,000 participant Estimated number participate institution : 150 medical institution Research secretariat : Mebix , Inc. Research procedure : - Perform patient registration within 3 week first prescription - Also record drug discontinue reason , event bleeding etc , time first prescription registration - Track progress much possible end study period , regardless continuation discontinuation study drug administration , also case manifestation efficacy safety event - Track progress case much possible end study period , regardless continuation , discontinuation termination study drug administration . Patients transfer hospital manage way . Registration method : Register case information WEB registration system ( EDC ) obtain write consent research participant him/herself legal guardian case compliant registration criterion conflict exclusion criterion . Administer rivaroxaban compliance approve dosage separate attach document . Furthermore , usage dose adjust discretion research doctor , record dose adjustment reason . EDC use case data entry . [ EDC ; Items enter case registration screen ] 1 . Registration date 2 . Facility name 3 . Case registration number 4 . Patient identification code ( appropriate number within facility ) 5 . Gender 6 . Birthdate 7 . Rivaroxaban commencement date 8 . Age first prescription ( automatic calculation display ) 9 . Date obtain write consent 10 . Other</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>1 . Symptomatic asymptomatic venous thromboembolism prescribe rivaroxaban 1 . Contraindication rivaroxaban 2 . Chronic thromboembolic pulmonary hypertension ( however , possible register coexist acute pulmonary embolism deep vein thrombosis ) 3 . Active bleed 4 . Patients determine inappropriate study attend doctor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Deep Vein Thrombosis</keyword>
	<keyword>pulmonary embolism</keyword>
</DOC>